المؤلفون: Gaborit B; Nantes Université, CHU Nantes, INSERM, Department of Infectious Diseases, Nantes, France.; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, Nantes, France., Vanhove B; Xenothera, Nantes, France., Lacombe K; INSERM, AP-HP, Hôpital Saint-Antoine, Service des Maladies Infectieuses et Tropicales, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Sorbonne Université, Paris, France., Guimard T; Infectious Diseases and Emergency Department, Centre Hospitalier de La Roche sur Yon, La Roche sur Yon, France., Hocqueloux L; CHU d'Orléans, Department of Infectious Diseases, Orleans, France., Perrier L; Nantes Université, CHU Nantes, Sponsor Department, Direction de la Recherche et de l'Innovation, Nantes, France., Dubee V; Service de Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire d'Angers, Angers, France.; Univ Angers, Nantes Université, INSERM, Immunology and New Concepts in ImmunoTherapy, INCIT, Angers, France., Ferre V; Nantes Université, CHU Nantes, Virology Laboratory, Nantes, France., Bressollette C; Nantes Université, CHU Nantes, Virology Laboratory, Nantes, France., Josien R; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, Nantes, France.; Nantes Université, CHU Nantes, Laboratoire d'Immunologie, CIMNA, Nantes, France., Thuaut AL; Nantes Université, CHU Nantes, Sponsor Department, Direction de la Recherche et de l'Innovation, Nantes, France.; Nantes Université, CHU Nantes, Plateforme de Méthodologie et Biostatistique, Direction de la Recherche et de l'Innovation, Nantes, France., Vibet MA; Nantes Université, CHU Nantes, Sponsor Department, Direction de la Recherche et de l'Innovation, Nantes, France.; Nantes Université, CHU Nantes, Plateforme de Méthodologie et Biostatistique, Direction de la Recherche et de l'Innovation, Nantes, France., Jobert A; Nantes Université, CHU Nantes, Sponsor Department, Direction de la Recherche et de l'Innovation, Nantes, France.; Nantes Université, CHU Nantes, UMR 1246 MethodS in Patients-centered outcomes and HEalth Research,' SPHERE, Nantes, France., Dailly E; Nantes Université, CHU Nantes, Clinical Pharmacology Department, Nantes, France., Ader F; CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Centre International de Recherche en Infectiologie (CIRI), Inserm 1111, Université Claude Bernard Lyon 1, Université Lyon, Lyon, France.; Département des Maladies Infectieuses et Tropicales, Hospices Civils de Lyon, Lyon, France., Brouard S; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, Nantes, France., Duvaux O; Xenothera, Nantes, France., Raffi F; Nantes Université, CHU Nantes, INSERM, Department of Infectious Diseases, Nantes, France.

مؤلفون مشاركون: POLYCOR study group

المصدر: Open forum infectious diseases [Open Forum Infect Dis] 2023 Oct 20; Vol. 10 (11), pp. ofad525. Date of Electronic Publication: 2023 Oct 20 (Print Publication: 2023).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Published by Oxford University Press on behalf of the Infectious Diseases Society of America Country of Publication: United States NLM ID: 101637045 Publication Model: eCollection Cited Medium: Print ISSN: 2328-8957 (Print) Linking ISSN: 23288957 NLM ISO Abbreviation: Open Forum Infect Dis Subsets: PubMed not MEDLINE

المؤلفون: Laurent M; Internal Medicine and Geriatric Department, Henri-Mondor Hospital, APHP, Créteil, France; CEpiA (Clinical Epidemiology and Aging) Unit, UPEC A-TVB DHU, IMRB,EA 7376 CEpiA University Paris Est (UPE), Créteil, France. Electronic address: marie.laurent@aphp.fr., Brureau L; Medicine Department, Gustave Roussy Cancer Center, Villejuif, France., Demery ME; Department of Oncology, Clinique du Cap d'Or, La Seyne sur Mer, France., Fléchon A; Department of Medical Oncology, Leon Bérard Cancer Center, Lyon, France., Thuaut AL; CEpiA (Clinical Epidemiology and Aging) Unit, UPEC A-TVB DHU, IMRB,EA 7376 CEpiA University Paris Est (UPE), Créteil, France; Public Health Department, Henri-Mondor Hospital, APHP, Créteil, France; Clinical Research Unit (URC Mondor), Henri-Mondor Hospital, APHP, Créteil, France., Carvahlo-Verlinde M; Department of Pharmacy, Henri-Mondor Hospital, APHP, Créteil, France., Bastuji-Garin S; CEpiA (Clinical Epidemiology and Aging) Unit, UPEC A-TVB DHU, IMRB,EA 7376 CEpiA University Paris Est (UPE), Créteil, France; Public Health Department, Henri-Mondor Hospital, APHP, Créteil, France; Clinical Research Unit (URC Mondor), Henri-Mondor Hospital, APHP, Créteil, France., Paillaud E; Internal Medicine and Geriatric Department, Henri-Mondor Hospital, APHP, Créteil, France; CEpiA (Clinical Epidemiology and Aging) Unit, UPEC A-TVB DHU, IMRB,EA 7376 CEpiA University Paris Est (UPE), Créteil, France., Canoui-Poitrine F; CEpiA (Clinical Epidemiology and Aging) Unit, UPEC A-TVB DHU, IMRB,EA 7376 CEpiA University Paris Est (UPE), Créteil, France; Public Health Department, Henri-Mondor Hospital, APHP, Créteil, France; Clinical Research Unit (URC Mondor), Henri-Mondor Hospital, APHP, Créteil, France., Culine S; Department of Medical Oncology, Saint-Louis Hospital, AP-HP, Paris, France; University Paris Diderot, Paris, France.

المصدر: Urologic oncology [Urol Oncol] 2017 Jan; Vol. 35 (1), pp. 34.e9-34.e16. Date of Electronic Publication: 2016 Oct 06.

نوع المنشور: Journal Article; Multicenter Study

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 9805460 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2496 (Electronic) Linking ISSN: 10781439 NLM ISO Abbreviation: Urol Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Withholding Treatment*, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Urinary Bladder Neoplasms/*drug therapy , Urinary Bladder Neoplasms/*mortality, Age Factors ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Carboplatin/administration & dosage ; Cisplatin/administration & dosage ; Creatinine/blood ; Creatinine/urine ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Female ; Health Status ; Humans ; Male ; Neoplasm Metastasis ; Prospective Studies ; Serum Albumin/metabolism ; Survival Rate ; Time Factors ; Tumor Burden ; Urinary Bladder Neoplasms/pathology ; Gemcitabine